Nahid Sultana

Employment

• University of The Pacific Graduate assiatant
  2017 - Present
• Eskayef Bangladesh Ltd. Product development executive

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (12)

• Targeting the Cell Cycle, RRM2 and NF-κB for the Treatment of Breast Cancers
  Cancers 2024 DOI: 10.3390/cancers16050975
  +Save
• Data from Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer
  2023 DOI: 10.1158/1535-7163.c.6543531.v1
  +Save
• Data from Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer
  2023 DOI: 10.1158/1535-7163.c.6543531
  +Save
• Figure S1 from Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer
  2023 DOI: 10.1158/1535-7163.22522959.v1
  +Save
• Figure S1 from Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer
  2023 DOI: 10.1158/1535-7163.22522959
  +Save
• Figure S2 from Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer
  2023 DOI: 10.1158/1535-7163.22522956.v1
  +Save
• Figure S2 from Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer
  2023 DOI: 10.1158/1535-7163.22522956
  +Save
• Figure S3 from Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer
  2023 DOI: 10.1158/1535-7163.22522953.v1
  +Save
• Figure S3 from Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer
  2023 DOI: 10.1158/1535-7163.22522953
  +Save
• Supplementary Methods from Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer
  2023 DOI: 10.1158/1535-7163.22522950
  +Save